The US FDA has approved icodec-abae, a long-acting human insulin analog indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Insulin icodec-abae injection is the first-ever once-weekly basal insulin approved by the FDA.
Clinical evidence In a clinical trial involving approximately 2,680 adults with uncontrolled type 2 diabetes, once-weekly icodec-abae showed effective A1C reduction comparable to daily basal insulin, with a safety profile consistent with the basal insulin class. Dosage and administration Available in subcutaneous injection form Administered once-weekly Inject icodec-abae subcutaneously into the thigh, upper arm, or abdomen Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis Closely monitor glucose when switching to icodec-abae Contraindications Hypersensitivity During…
